

Julie B Dumond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4071542/publications.pdf>

Version: 2024-02-01

36
papers

896
citations

623734

14
h-index

454955

30
g-index

36
all docs

36
docs citations

36
times ranked

990
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. <i>Aids</i> , 2007, 21, 1899-1907.	2.2	177
2	Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 546-553.	2.1	122
3	Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men. <i>Journal of Infectious Diseases</i> , 2011, 203, 1484-1490.	4.0	83
4	Pre-exposure prophylaxis for HIV prevention: how to predict success. <i>Lancet, The</i> , 2012, 379, 2409-2411.	13.7	64
5	Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2367-2374.	3.2	56
6	Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 39-44.	2.1	48
7	Differential Extracellular and Intracellular Concentrations of Zidovudine and Lamivudine in Semen and Plasma of HIV-1-Infected Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 156-162.	2.1	41
8	Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. <i>Antiviral Therapy</i> , 2013, 18, 1005-1013.	1.0	32
9	Pharmacokinetic Modelling of Efavirenz, Atazanavir, Lamivudine and Tenofovir in the Female Genital Tract of HIV-Infected Pre-Menopausal Women. <i>Clinical Pharmacokinetics</i> , 2012, 51, 809-822.	3.5	30
10	Effect of Tropicam Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2017, 23, 118-123.	1.1	30
11	Effect of Anticholinergic Use for the Treatment of Overactive Bladder on Cognitive Function in Postmenopausal Women. <i>Clinical Drug Investigation</i> , 2012, 32, 697-705.	2.2	23
12	Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3527-3533.	3.2	21
13	Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. <i>HIV Medicine</i> , 2013, 14, 401-409.	2.2	20
14	Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 784-788.	3.2	15
15	A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 245-251.	2.5	14
16	Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 821-830.	4.7	13
17	Effect of Anticholinergic Use for the Treatment of Overactive Bladder on Cognitive Function in Postmenopausal Women. <i>Clinical Drug Investigation</i> , 2012, 32, 1.	2.2	12
18	A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. <i>Clinical and Translational Science</i> , 2022, 15, 1304-1315.	3.1	12

#	ARTICLE	IF	CITATIONS
19	The effect of age on CD4+ T-cell recovery in HIV-suppressed adult participants: a sub-study from AIDS Clinical Trial Group (ACTG) A5321 and the Bone Loss and Immune Reconstitution (BLIR) study. <i>Immunity and Ageing</i> , 2022, 19, 4.	4.2	8
20	Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6395-6401.	3.2	7
21	Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 128-135.	2.5	7
22	Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?. <i>Clinical and Translational Science</i> , 2018, 11, 226-236.	3.1	7
23	Implementation and Initial Evaluation of a Research and Scholarship Training Pathway in a Doctor of Pharmacy Curriculum. <i>American Journal of Pharmaceutical Education</i> , 2021, 85, 8079.	2.1	7
24	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 510-514.	2.1	6
25	p16 INK4a , a Senescence Marker, Influences Tenofovir/Emtricitabine Metabolite Disposition in HIV-Infected Subjects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 120-127.	2.5	6
26	Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. <i>Antiviral Therapy</i> , 2018, 24, 45-50.	1.0	6
27	Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. <i>PLoS ONE</i> , 2016, 11, e0168709.	2.5	5
28	Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16 ^{INK4a} Expression in Subjects on Combination Therapy. <i>Antiviral Therapy</i> , 2016, 21, 441-445.	1.0	5
29	Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 913-922.	2.5	5
30	Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 631-640.	1.8	4
31	Model-Based Analysis of Unbound Lopinavir Pharmacokinetics in HIV-Infected Pregnant Women Supports Standard Dosing in the Third Trimester. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 147-157.	2.5	3
32	Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
33	Unexpectedly low levels of transplacental transfer of second-generation integrase strand transfer inhibitors bictegravir and cabotegravir. <i>Aids</i> , 2020, 34, 2137-2139.	2.2	2
34	Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. <i>Pharmacotherapy</i> , 2023, 43, 638-649.	2.6	2
35	DÃ©jà vu all over again. <i>Aids</i> , 2019, 33, 2097-2098.	2.2	0
36	The potential pitfalls of PrEP. <i>Lancet HIV</i> , 2019, 6, e6-e8.	4.7	0